275 related articles for article (PubMed ID: 17382266)
1. Nuclear imaging of neuroendocrine tumours.
Sundin A; Garske U; Orlefors H
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
[TBL] [Abstract][Full Text] [Related]
2. PET in the diagnosis of neuroendocrine tumors.
Sundin A; Eriksson B; Bergström M; Långström B; Oberg K; Orlefors H
Ann N Y Acad Sci; 2004 Apr; 1014():246-57. PubMed ID: 15153441
[TBL] [Abstract][Full Text] [Related]
3. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
[TBL] [Abstract][Full Text] [Related]
4. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.
Orlefors H; Sundin A; Garske U; Juhlin C; Oberg K; Skogseid B; Langstrom B; Bergstrom M; Eriksson B
J Clin Endocrinol Metab; 2005 Jun; 90(6):3392-400. PubMed ID: 15755858
[TBL] [Abstract][Full Text] [Related]
5. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
6. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?
Santhanam P; Chandramahanti S; Kroiss A; Yu R; Ruszniewski P; Kumar R; Taïeb D
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1144-55. PubMed ID: 25771906
[TBL] [Abstract][Full Text] [Related]
7. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
Oberg K; Eriksson B
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
[TBL] [Abstract][Full Text] [Related]
8. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
9. Nuclear medicine imaging of neuroendocrine tumours.
Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
[TBL] [Abstract][Full Text] [Related]
10. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
11. Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.
Toumpanakis C; Kim MK; Rinke A; Bergestuen DS; Thirlwell C; Khan MS; Salazar R; Oberg K
Neuroendocrinology; 2014; 99(2):63-74. PubMed ID: 24458014
[TBL] [Abstract][Full Text] [Related]
12. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
13. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
14. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data.
Talbot JN; Kerrou K; Missoum F; Grahek D; Aide N; Lumbroso J; Montravers F
Mol Imaging Biol; 2005; 7(4):257-61. PubMed ID: 16082495
[TBL] [Abstract][Full Text] [Related]
15. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.
Koopmans KP; de Vries EG; Kema IP; Elsinga PH; Neels OC; Sluiter WJ; van der Horst-Schrivers AN; Jager PL
Lancet Oncol; 2006 Sep; 7(9):728-34. PubMed ID: 16945767
[TBL] [Abstract][Full Text] [Related]
16. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
17. Nuclear Medicine Imaging of Neuroendocrine Tumors.
Brabander T; Kwekkeboom DJ; Feelders RA; Brouwers AH; Teunissen JJ
Front Horm Res; 2015; 44():73-87. PubMed ID: 26303705
[TBL] [Abstract][Full Text] [Related]
18. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
Junik R; Drobik P; Małkowski B; Kobus-Błachnio K
Adv Med Sci; 2006; 51():66-8. PubMed ID: 17357280
[TBL] [Abstract][Full Text] [Related]
19. Contemporary nuclear medicine imaging of neuroendocrine tumours.
Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
[TBL] [Abstract][Full Text] [Related]
20. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Hicks RJ
Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]